Schedule 13D ownership disclosure

Kymera Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 501575104

Event date: 2025-06-26

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Baker Bros. Advisors LPReported CIK 0001263508

    Shares: 6,666,540.00 · Class: 9.5%

  • Baker Bros. Advisors (GP) LLCReported CIK 0001580575

    Shares: 6,666,540.00 · Class: 9.5%

  • Julian C. BakerReported CIK 0001087939

    Shares: 6,666,540.00 · Class: 9.5%

  • Felix J. BakerReported CIK 0001087940

    Shares: 6,666,540.00 · Class: 9.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-064298
Form type
SCHEDULE 13D/A
Filer
BAKER BROS. ADVISORS LP
CIK
CIK 1263508
Filed
Jun 30, 2025
Reporting period
Jun 26, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub